Skip to NavigationSkip to content

Mylan launches generic of Valeant’s Ultram in the US

Published on 29/03/16 at 10:01am

Mylan (NASDAQ, TASE: MYL) has announced the launch of its generic version of Valeant’s Ultram tablets in the US.

The company received final approval from the US Food and Drug Administration for its tramadol hydrochloride extended-release tablets USP, which is indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

According to IMS Health, tramadol hydrochloride extended-release tablets USP had US sales of approximately $52.8 million for the 12 months to 31st December 2015.

Mylan currently has 265 abbreviate new drug applications pending FDA approval, which represent £110.3 billion in annual brand sales, according to the research body.

Sean Murray

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches